Dr. Joshua D. Lee is an associate professor in the Departments of Population Health and Medicine at the NYU Grossman School of Medicine and director of the NYU Fellowship in Addiction Medicine. Dr. Lee is a clinician-researcher focused on investigating addiction pharmacotherapies in primary care and criminal justice system-involved populations. He has conducted multiple NIH clinical trials examining the use of naltrexone and buprenorphine opioid and alcohol treatments in criminal justice system-involved adults, at community re-entry, and within primary care settings.

Ryan D. McDonald is the Lee Lab program manager and oversees Dr. Joshua Lee’s research team. Ryan has managed several NIH clinical trials examining naltrexone and buprenorphine opioid treatments in community criminal justice involved adults, at release from jail, and within community primary care settings. He received his MA in forensic psychology from the John Jay College of Criminal Justice.

Mia Malone is a Lee Lab project manager who aids in the management of all research projects. Mia has worked on several NIH clinical trials such as examining the effectiveness of extended-release naltrexone versus oral naltrexone for the treatment of alcohol dependence and the current Lee Lab study evaluating the feasibility and efficacy of extended-release buprenorphine versus daily sublingual buprenorphine for the treatment of opioid use disorder among people released from NYC jails. Prior to joining the Lee Lab in 2016, Mia worked with Dr. Scott Sherman at NYU Grossman School of Medicine investigating smoking cessation interventions for the veteran population. Mia graduated from New York University with a bachelor’s degree in psychology and anthropology.

Anna Cheng is a Lee Lab research coordinator. Anna conducts patient visits in a study evaluating the effectiveness of extended-release buprenorphine for the treatment of opioid use disorder among people released from New York City jails. Anna graduated from Cornell University with a bachelor of science degree in human biology, health, and society. She previously counseled underserved elementary school children in the Ithaca community and taught criminal justice-involved adults in prison education settings.

Nadina Santana-Correa, a Lee Lab research coordinator, works on a study evaluating the feasibility and efficacy of extended-release buprenorphine versus daily sublingual buprenorphine for the treatment of opioid use disorder among people released from NYC jails. She previously worked on a study evaluating the effectiveness of extended-release naltrexone in reducing opioid relapse among people released from NYC jails. She has worked on large clinical trials investigating treatment interventions for people with substance use disorders.

Wanda Bonilla is a Lee Lab research coordinator who works on a study evaluating the feasibility and efficacy of extended-release buprenorphine vs. daily sublingual buprenorphine for the treatment of opioid use disorder among people released from NYC jails. Wanda also worked on a study evaluating the effectiveness of extended-release naltrexone in reducing opioid relapse among people released from NYC jails. She has previously worked on research on treatment for people with addiction disorders and performed case management and counseling for social service organizations in New York City.

James Swift is a participant tracker for the Lee Lab and currently works on a study evaluating the feasibility and efficacy of extended-release buprenorphine versus daily sublingual buprenorphine for the treatment of opioid use disorder among people released from NYC jails. James works in the community to locate participants, facilitate contact with the research team,  and coordinate study care.